Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Mark A. Goldsmith will engage in a fireside chat on November 15 at 2:40 p.m. Eastern. The company focuses on developing drugs that target RAS-addicted cancers through innovative drug discovery capabilities. Its R&D pipeline features RAS(ON) Inhibitors like RMC-6291 and RMC-6236, along with various RAS Companion Inhibitors, aimed at enhancing cancer treatment strategies.

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming Stifel 2021 Virtual Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Details of these company’s participation are as follows:

• Stifel 2021 Virtual Healthcare Conference
  Conference Date: November 15-17, 2021
  Fireside Chat Time/Date: 2:40 p.m. Eastern on Monday, November 15, 2021
  Format: Virtual conference

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

FAQ

When will Revolution Medicines participate in the Stifel 2021 Virtual Healthcare Conference?

Revolution Medicines will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021.

What time is the fireside chat at the Stifel 2021 Virtual Healthcare Conference for RVMD?

The fireside chat for Revolution Medicines (RVMD) is scheduled for November 15, 2021, at 2:40 p.m. Eastern.

What is the main focus of Revolution Medicines?

Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers.

What are some RAS(ON) Inhibitors in Revolution Medicines' pipeline?

RAS(ON) Inhibitors in development include RMC-6291 and RMC-6236.

What types of therapies are RAS Companion Inhibitors?

RAS Companion Inhibitors are designed for use in combination treatment strategies for cancer.